Molecular Crosstalk Between Adhesion Receptors and Proteolytic Cascades in Vascular Remodelling

K T Preissner; A E May; K D Wohn; M Germer; S M Kanse

doi:10.1055/s-0038-1657507

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(01): 088-095
DOI: 10.1055/s-0038-1657507

Integrin signalling and vascular function

Schattauer GmbH Stuttgart

Molecular Crosstalk Between Adhesion Receptors and Proteolytic Cascades in Vascular Remodelling

K T Preissner

Max-Planck-lnstitut, Bad Nauheim, Germany

,

A E May

Max-Planck-lnstitut, Bad Nauheim, Germany

,

K D Wohn

Max-Planck-lnstitut, Bad Nauheim, Germany

,

M Germer

Max-Planck-lnstitut, Bad Nauheim, Germany

,

S M Kanse

Max-Planck-lnstitut, Bad Nauheim, Germany

› Author Affiliations

Abstract

PDF Download

PDF (1748 kb)

References

References
1 Folkman J, D’Amore PA. Blood vessel formation: What is its molecular basis?. Cell 1996; 87: 1153-1155
2 Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol 1996; 6: 454-456
3 Fässler R, Georges-Labouesse E, Hirsch E. Genetic analysis of integrin function in mice. Curr Opin Cell Biol 1996; 8: 641-646
4 Woods A, Couchman JR. Signaling from the matrix to the cytoskeleton-role of cell surface proteoglycans in matrix assembly. Kidney Intern 1996; 49: 64-67
5 Couchman JR, Woods A. Syndecans, signaling, and cell adhesion. J Cell Biochem 1996; 61: 578-584
6 Humphries MJ. The molecular basis and specificity of integrin-ligand interactions. J Cell Sci 1990; 97: 585-592
7 Lafrenie RM, Yamada KM. Intgrin-dependent signal transduction. J Cell Biochem 1996; 61: 543-553
8 Ruoslahti E. Integrin signaling and matrix assembly. Tumor Biol 1996; 17: 117-124
9 Hynes RO. Integrins:Versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25
10 Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis?. Cell 1989; 58: 803-805
11 Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 5: 864-868
12 Davis CM, Danehower SC, Laurenza A, Molony JL. Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation. J Cell Biol 1993; 51: 206-218
13 Casaroli Marano RP, Preissner KT, Vilaro S. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 1995; 60: 05-17
14 Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164
15 Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953-961
16 Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 1994; 127: 537-546
17 Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclic E-CDK2 kinase activity on cell anchorage. Science 1996; 271: 499-502
18 Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAFl/CIPl expression by vascular ell integrin αvβ3 during angiogenesis. J Clin Invest 1996; 98: 426-433
19 Senger DR. Molecular framework for angiogenesis. A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Path 1996; 149: 1-7
20 Davis GE. Affinity of integrins for damaged extracellular matrix αvβ3 binds to denatured collagen type-I through RGD sites. Biochem Biophys Res Commun 1992; 182: 1025-1031
21 Koyama H, Raines EW, Bomfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996; 87: 1069-1078
22 Miyamoto S, Akiyama SK, Yamada KM. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science 1995; 267: 883-885
23 Preissner KT. Structure and biological role of vitronectin. Ann Rev Cell Biol 1991; 7: 275-310
24 Tomasini BR, Mosher DF. Vitronectin. Prog Hemostas Thromb 1990; 10: 269-305
25 Hess S, Kanse SM, Kost C, Preissner KT. The versatility of adhesion receptor ligands in haemostasis: morpho-regulatory functions of vitronectin. Thromb Haemostas 1995; 74: 258-265
26 Lim BL, Reid KBM, Ghebrehiwet B, Peerschke EIB, Leight LAE, Preissner KT. The binding protein for globular heads of complement Clq, gClqR. Functional expression and characterization as a novel vitronectin binding factor. J Biol Chem 1996; 271: 26739-26744
27 Zanetti A, Conforti G, Hess S, Martinpadura I, Ghibaudi E, Preissner KT, Dejana E. Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane. Blood 1994; 84: 1116-1123
28 Bhattacharya S, Fu C, Bhattacharya J, Greenberg S. Soluble ligands of the avβ3 integrin mediate enhanced tyrosine phosphorylation of multiple proteins in adherent bovine pulmonary artery endothelial cells. J Biol Chem 1995; 28: 16781-16787
29 Sage EH, Bomstein P. Extracellular proteins that modulate cell-matrix interactions:spare, tenascin, and thrombospondin. J Biol Chem 1991; 266: 14831-14834
30 Iruela-Arispe ML, Bomstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 5026-5030
31 Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993; 1182: 01-14
32 Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 1994; 269: 26775-26782
33 Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994; 125: 929-943
34 Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by α2β1 and αVβ3 integrins. J Cell Sci 1993; 105: 1001-1012
35 Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-c. J Cell Biol 1994; 126: 539-548
36 Rosenblatt S, Bassuk JA, Alpers CE, Sage EH, Timpl R, Preissner KT. Differential modulation of cell adhesion by interaction between adhesive and counteradhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem J. in press.
37 Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiological characterization of angiogenic vessels in mice. Am J Pathol 1996; 149: 59-71
38 Chen WT. Membrane proteases:roles in tissue remodeling and tumour invasion. Curr Opin Cell Biol 1992; 4: 802-809
39 Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1996; 7: 728-735
40 Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989; 108: 671-682
41 Mimuro J, Loskutoff DJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem 1989; 264: 5058-5063
42 Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, Pannekoek H, Müller-Berghaus G. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498
43 Rovelli G, Stone SR, Preissner KT, Monard D. Specific interaction of vitronectin with the cell-secreted protease inhibitor glia-derived nexin (GDN and the GDN-thrombin complex. Eur J Biochem 1990; 192: 797-803
44 Baker JB, Low DA, Simmer RL, Cunningham DD. Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980; 21: 37-45
45 Mackay AR, Ballin M, Pellina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis 1992; 12: 168-184
46 Mattsson E, Clowes AW. Current concepts in restenosis following balloon angioplasty. Trends Cardiovasc Med 1995; 5: 200-204
47 Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood 1994; 83: 3427-3436
48 Korner G, Bjomsson TD, Vlodavsky I. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plaminogen activators. J Cell Physiol 1993; 154: 456-465
49 Quigley JP, Gold LI, Schwimmer R, Sullivan LM. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 1987; 84: 2776-2780
50 Moller LB. Structure and function of the urokinase receptor. Blood Coagul Fibrin 1993; 4: 293-303
51 Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K. Urokinase-receptor biosynthesis, messenger-RNA level and gene transcription are increased by transforming growth factor β1 in human A549 lung-carcinoma cells. EMBO J 1991; 10: 3399-3407
52 Ossowski L, Clunie G, Masucci M, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1993; 115: 1107-1112
53 Montesano R, Pepper MS, Möhle-Steinlein U, Risau W, Wagner EF, Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990; 62: 435-445
54 Moser TL, Enghild JJ, Pizzo SV, Stack MS. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem 1993; 268: 18917-18923
55 Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen tissue-plasminogen activator (t-pa2). annexin ii-mediated enhancement of t-pa-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203
56 Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: Identification of α-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 1682-1691
57 Vaheri A, Stephens RW, Salonen EM, Pöllänen J, Tapiovaara H. Plasminogen activation at the cell surface-matrix interface. Cell Diff Dev 1990; 32: 255-262
58 Kost C, Benner K, Stockmann A, Linder D, Preissner KT. Limited plasmin proteolysis of vitronectin: characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur J Biochem 1996; 236: 682-688
59 Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Develop 1995; 9: 794-807
60 O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328
61 Miles LA, Plow EF. Lp(a) — an interloper into the fibrinolytic system. Thromb Haemost 1990; 63: 331-335
62 Orth K, Madison LE, Gething M, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator with PAI-1 are internalized by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89: 7422-7426
63 Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-18229
64 Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460-462
65 Brown E, Hooper L, Ho T, Gresham H. Integrin-associated protein: A 50-kD plasma membrane antigen physically and functionally associated with integrins. J Cell Biol 1990; 111: 2785-2794
66 Yebra M, Party GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvjβ5-directed cell migration. J Biol Chem 1996; 271: 29393-29399
67 Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555
68 Pöllänen J, Hedman K, Nielsen LS, Dano K, Vaheri A. Ultra-structural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988; 106: 87-95
69 Pöllänen J, Saksela O, Salonen EM, Andreasen P, Nielsen L, Dano K, Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987; 104: 1085-1096
70 Ciambrone GJ, McKeown-Longo PJ. Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J Cell Biol 1990; 111: 2183-2195
71 Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992; 267: 13617-13622
72 Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991; 57: 273-328
73 Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth-factor. J Cell Biol 1991; 113: 1193-1201
74 Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, Mignatti P, Pepper MS. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995; 270: 9709-9716
75 Pepper MS, Sappino AP, Stocklin R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993; 122: 673-684
76 Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli J-D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111: 783-792
77 Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93: 1380-1387
78 Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993; 91: 1541-1552
79 Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-353
80 Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-14750
81 Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J Cell Biol 1996; 134: 1563-1571
82 Preissner KT. Vitronectin as link between protease cascades and cell adhesion in haemostasis. in Vascular Control of Hemostasis. van Hinsbergh VWM. (ed) Amsterdam: Harwood Academic; 1996. pp 169-186
83 Moser TL, Enghild JJ, Pizzo SV, Stack MS. Specific binding of urinary-type plasminogen activator (u-PA to vitronectin and its role in mediating u-PA depnedent adhesion of U937 cells. Biochem J 1995; 307: 867-873
84 Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388
85 Brooks PC, Strömblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasisve cells by interaction with integrin αvβ3. Cell 1996; 85: 683-693
86 Piali L, Hammel PM, Uherek C, Bachmann F, Gisler RH, Dunon D, Imhof BA. CD31/PECAM-1 is a ligand for αvβ3-integrin involved in adhesion of leukocytes to endotheliu. J Cell Biol 1995; 130: 451-460
87 Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. in press.
88 Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell megration by blocking integrin αvβ3 binding to vitronectin. Nature 1996; 383: 441-443
89 Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78
90 Duffy MJ, Reilly D, Mcdermott E, Ohiggins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994; 74: 2276-2280
91 Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system:implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 1995; 9: 934-938
92 Carmeliet P, Collen D. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. Trends Cardiovasc Med 1995; 5: 117-122
93 Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 1995; 92: 12426-12430
94 Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost. in press.
95 Leven RM, Tablin F. Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Hematol 1992; 20: 1316-1322
96 Leven RM. Differential regulation of integrin-mediated proplatelet formation and megakaryocyte spreading. J Cell Physiol 1995; 163: 597-607
97 Cao DR, Mizukami IF, Garniwagner BA, Kindzelskii AL, Todd RF, Boxer LA, Petty HR. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release — possible roles of complement receptor type 3 and calcium. J Immunol 1995; 154: 1817-1829
98 Dumler I, Petri T, Schleuning W-D. Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR)induces phosphorylation on tyrosine of a 38 kDA protein. FEBS Lett 1993; 322: 37-40
99 Petty HR, Todd RF. Integrins as promiscuous signal transduction devices. Immunol Today 1996; 17: 209-212
100 Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, β2-integrins, and scr-kinases within a single receptor complex of human monocytes. J Exp Med 1995; 181: 1381-1390
101 Higazi AA-R, Upson RH, Cohen RL, Manuppello J, Bognacki J, Henkin J, McCrae KR, Kounnas MZ, Strickland DK, Preissner KT, Lawler J, Cines DB. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 1996; 88: 542-551
102 Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15: 1572-1582
103 Sitrin RG, Todd RF, Petty HR, Brock TG, Shollenberger SB, Albrecht E, Gyetko MR. The urokinase receptor (CD87)facilitates CD11B/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97: 1942-1951
104 Meredith JE, Winitz S, McArthur Lewis J, Hess S, Ren XD, Renshaw MW, Schwartz MA. The regulation of growth and intracellular signaling by integrins. Endocrinol Rev 1996; 17: 207-220
105 Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antangonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433
106 Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jäggle C, Moyano JM, Kreysch H, Piulats J, Goodman SL. An anti-av-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108: 2825-2838
107 Strömblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6: 462-467
108 Montesano R. Regulation of angiogenesis in vitro. Eur J Clin Invest 1992; 22: 504-515
109 Hammes HP, Brownlee M, Joncyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996; 2: 529-533
110 Choi EngelL, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vase Surg 1994; 19: 125-134
111 Hynes RO, George EL, Georges EN. et al Toward a genetic analysis of cell-matrix adhesion. in Cold Spring Harbor Symposia on Quantitative Biology. CSH Press; 1992. pp 249-257
112 Preissner KT, Kanse SM. Protease receptors in the vasculature: Novel molecular links for the regulation of haemostasis and wound repair processes. Biomed Progr 1996; 9: 22-27
113 Panetti TS, McKeown-Longo PJ. The αvβ5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 11492-11495
114 de Boer HC, Preissner KT, Bouma BN, de Groot PG. Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. J Biol Chem 1995; 30733-30740